11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
January 2025 in “International Journal of Medicine in Developing Countries” Ocrelizumab may cause delayed hair loss in some patients.
9 citations
,
May 2021 in “International Journal of Dermatology” The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
6 citations
,
October 2021 in “Brain Sciences” Dutasteride may help reduce brain inflammation and improve cognition.
26 citations
,
January 2012 in “Journal of the American Academy of Dermatology” Eflornithine cream makes laser hair removal more effective for treating pseudofolliculitis barbae.
December 2023 in “Acta dermato-venereologica” Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
August 2024 in “British Journal of Dermatology” Rezpegaldesleukin shows promise for treating severe alopecia areata.
29 citations
,
December 2019 in “Expert review of clinical pharmacology” JAK inhibitors are a promising new treatment for hair loss and nail problems in alopecia areata.
August 2002 in “Dermatologic Surgery” Fluridil safely promotes hair growth in men with androgenetic alopecia.
November 2024 in “Rheumatology Advances in Practice” Ocrelizumab helped control lupus in a pregnant patient, leading to the birth of a healthy baby.
April 2025 in “Frontiers in Immunology” Tofacitinib effectively regrows hair in alopecia areata but may need continuous use.
2 citations
,
June 2019 in “Boletín médico del Hospital Infantil de México” Tofacitinib treatment is used for teenagers with alopecia areata.
October 2025 in “Clinical and Experimental Dermatology” Fibrosing alopecia can be stabilized or improved with anti-inflammatory treatments and hair growth agents.
April 2018 in “Journal of Investigative Dermatology” Anigozanthos Flavidus flower extract helps regenerate skin and reduce wrinkles.
November 2023 in “Indian Dermatology Online Journal” Tofacitinib was effective for severe, treatment-resistant hair loss without side effects.
71 citations
,
May 2024 in “New England Journal of Medicine” Ruxolitinib may effectively treat APS-1 by reducing harmful immune responses.
Frontal fibrosing alopecia can be managed with personalized combination therapies, but no cure exists yet.
26 citations
,
October 2016 in “Case Reports in Dermatology” A man with severe hair loss saw hair and nail improvement after 10 months on tofacitinib without side effects.
6 citations
,
March 2019 in “JAAD case reports” A new mix of anthralin and calcipotriene might help treat severe hair loss.
1 citations
,
April 2017 in “Journal of Investigative Dermatology” Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.
42 citations
,
April 2011 in “Annals of Pharmacotherapy” Flutamide effectively treats female pattern hair loss with low doses showing good liver tolerance.
7 citations
,
October 2015 in “Actas Dermo-Sifiliográficas” New treatments for Frontal Fibrosing Alopecia show promise, especially finasteride and dutasteride, with most patients seeing improvement or stabilization.
4 citations
,
August 2024 in “Cells” Inflammasome proteins can predict inflammation and outcomes in aneurysmal subarachnoid hemorrhage.
April 2026 in “Clinical and Experimental Dermatology” Dupilumab effectively reduces symptoms of prurigo nodularis and is safe for long-term use.
2 citations
,
May 2023 in “Journal of Immunotherapy” Sintilimab treatment caused hair loss but led to complete tumor remission.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.
45 citations
,
July 2002 in “The Neurologist” A comprehensive approach to educating patients and managing side effects is crucial for improving adherence to multiple sclerosis treatments and patient quality of life.
August 2018 in “Journal of Investigative Dermatology” Tofacitinib may help regrow hair in alopecia areata patients.
July 2025 in “Journal of Investigative Dermatology” Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.
4 citations
,
September 2025 in “Journal of the American Academy of Dermatology”